A Phase II Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antiretroviral Activity of DermaVir Patch (LC002) ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2008-2015

ABSTRACT

DermaVir is a synthetic pathogen-like nanomedicine. The active pharmaceutical ingredient is a single plasmid DNA expressing fifteen HIV antigens that assemble to HIV-like particles. These particles are safe; replication, integration and reverse transcription deficient. DermaVir is targeted to Langerhans cells by topical administration with DermaPrep. Langerhans cells with DermaVir migrate to lymph nodes and induce HIV-specific T cells that can kill HIV-infected cells. GIEU006 is a Phase II randomized, placebo-controlled, dose-finding, double-blinded, multicenter study to assess the safety, tolerability, immunogenicity, and preliminary antiretroviral activity of DermaVir in antiretroviral therapy naïve adults with HIV-infection. Detailed Description Patients were randomized into one of the following 6 arms: - Arm 1: Low dose DermaVir (0.2 mg DNA in 2 DermaPrep patches, n=9) - Arm 2: Low dose Placebo (2 DermaPrep patches, n=3) - Arm 3: Medium dose DermaVir (0.4 mg DNA in 4 DermaPrep patches, n=9) - Arm 4: Medium dose Placebo (4 DermaPrep patches, n=3) - Arm 5: High dose DermaVir (0.8 mg DNA in 8 DermaPrep patches, n=9) - Arm 6: High dose Placebo (8 DermaPrep patches, n=3) DermaPrep Patch size: 80 cm2. DermaVir Standard Unit per patch is 0.1 mg DNA = 0.8 mL of DermaVir nanomedicine. The patch sites for immunization are preferably the left or right upper back and left or right upper ventral thigh. The same skin sites should be used for all immunizations. Immunization schedule (Days): 0, 42, 84, and 126. The total DermaVir dose: - Low dose: 0.8 mg DNA - Medium dose: 1.6 mg DNA - High Dose: 3.2 mg DNA DermaVir immunizations were administered over an 18-week period Primary endpoint: 24 weeks Safety follow up: 234 weeks More... »

URL

https://clinicaltrials.gov/show/NCT00711230

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3053", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "DermaVir is a synthetic pathogen-like nanomedicine. The active pharmaceutical ingredient is a single plasmid DNA expressing fifteen HIV antigens that assemble to HIV-like particles. These particles are safe; replication, integration and reverse transcription deficient. DermaVir is targeted to Langerhans cells by topical administration with DermaPrep. Langerhans cells with DermaVir migrate to lymph nodes and induce HIV-specific T cells that can kill HIV-infected cells. GIEU006 is a Phase II randomized, placebo-controlled, dose-finding, double-blinded, multicenter study to assess the safety, tolerability, immunogenicity, and preliminary antiretroviral activity of DermaVir in antiretroviral therapy na\u00efve adults with HIV-infection.\n\nDetailed Description\nPatients were randomized into one of the following 6 arms: - Arm 1: Low dose DermaVir (0.2 mg DNA in 2 DermaPrep patches, n=9) - Arm 2: Low dose Placebo (2 DermaPrep patches, n=3) - Arm 3: Medium dose DermaVir (0.4 mg DNA in 4 DermaPrep patches, n=9) - Arm 4: Medium dose Placebo (4 DermaPrep patches, n=3) - Arm 5: High dose DermaVir (0.8 mg DNA in 8 DermaPrep patches, n=9) - Arm 6: High dose Placebo (8 DermaPrep patches, n=3) DermaPrep Patch size: 80 cm2. DermaVir Standard Unit per patch is 0.1 mg DNA = 0.8 mL of DermaVir nanomedicine. The patch sites for immunization are preferably the left or right upper back and left or right upper ventral thigh. The same skin sites should be used for all immunizations. Immunization schedule (Days): 0, 42, 84, and 126. The total DermaVir dose: - Low dose: 0.8 mg DNA - Medium dose: 1.6 mg DNA - High Dose: 3.2 mg DNA DermaVir immunizations were administered over an 18-week period Primary endpoint: 24 weeks Safety follow up: 234 weeks", 
    "endDate": "2015-01-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT00711230", 
    "keywords": [
      "Phase II", 
      "multi-center study", 
      "safety", 
      "tolerability", 
      "immunogenicity", 
      "antiretroviral activity", 
      "HIV-infected patient", 
      "nanomedicine", 
      "active pharmaceutical ingredient", 
      "plasmid", 
      "DNA", 
      "HIV antigen", 
      "particle", 
      "replication", 
      "integration", 
      "reverse transcription", 
      "Langerhans cell", 
      "topical administration", 
      "lymph node", 
      "HIV-specific T cell", 
      "HIV-infected cell", 
      "dose finding", 
      "multicenter study", 
      "antiretroviral therapy", 
      "HIV infection", 
      "patient", 
      "arm", 
      "Arm 1", 
      "low dose", 
      "patch", 
      "arm 2", 
      "Arm 3", 
      "medium", 
      "placebo", 
      "high dose", 
      "cm2", 
      "unit", 
      "Ml", 
      "immunization", 
      "right", 
      "skin", 
      "immunization schedule", 
      "dose", 
      "primary endpoint"
    ], 
    "name": "A Phase II Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antiretroviral Activity of DermaVir Patch (LC002) in Treatment-Na\u00efve HIV-1-Infected Patients", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT00711230"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:23", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00005.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.13648.38", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.459389.a", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.491914.0", 
        "type": "Organization"
      }
    ], 
    "startDate": "2008-04-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1016/j.vaccine.2005.01.004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000998801"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1111/j.0022-202x.2004.23535.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003763955", 
          "https://doi.org/10.1111/j.0022-202x.2004.23535.x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.nano.2012.05.012", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004651059"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00002030-200501030-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009052805"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.vaccine.2010.11.019", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011308805"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1586/erv.11.118", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029275935"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.vaccine.2007.01.024", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040396586"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.nano.2011.07.013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042808998"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijpharm.2010.03.048", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049047381"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0035416", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052753685"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT00711230"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT00711230'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT00711230'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT00711230'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT00711230'


 

This table displays all metadata directly associated to this object as RDF triples.

98 TRIPLES      16 PREDICATES      71 URIs      53 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT00711230 schema:about anzsrc-for:3053
2 schema:description DermaVir is a synthetic pathogen-like nanomedicine. The active pharmaceutical ingredient is a single plasmid DNA expressing fifteen HIV antigens that assemble to HIV-like particles. These particles are safe; replication, integration and reverse transcription deficient. DermaVir is targeted to Langerhans cells by topical administration with DermaPrep. Langerhans cells with DermaVir migrate to lymph nodes and induce HIV-specific T cells that can kill HIV-infected cells. GIEU006 is a Phase II randomized, placebo-controlled, dose-finding, double-blinded, multicenter study to assess the safety, tolerability, immunogenicity, and preliminary antiretroviral activity of DermaVir in antiretroviral therapy naïve adults with HIV-infection. Detailed Description Patients were randomized into one of the following 6 arms: - Arm 1: Low dose DermaVir (0.2 mg DNA in 2 DermaPrep patches, n=9) - Arm 2: Low dose Placebo (2 DermaPrep patches, n=3) - Arm 3: Medium dose DermaVir (0.4 mg DNA in 4 DermaPrep patches, n=9) - Arm 4: Medium dose Placebo (4 DermaPrep patches, n=3) - Arm 5: High dose DermaVir (0.8 mg DNA in 8 DermaPrep patches, n=9) - Arm 6: High dose Placebo (8 DermaPrep patches, n=3) DermaPrep Patch size: 80 cm2. DermaVir Standard Unit per patch is 0.1 mg DNA = 0.8 mL of DermaVir nanomedicine. The patch sites for immunization are preferably the left or right upper back and left or right upper ventral thigh. The same skin sites should be used for all immunizations. Immunization schedule (Days): 0, 42, 84, and 126. The total DermaVir dose: - Low dose: 0.8 mg DNA - Medium dose: 1.6 mg DNA - High Dose: 3.2 mg DNA DermaVir immunizations were administered over an 18-week period Primary endpoint: 24 weeks Safety follow up: 234 weeks
3 schema:endDate 2015-01-01T00:00:00Z
4 schema:keywords Arm 1
5 Arm 3
6 DNA
7 HIV antigen
8 HIV infection
9 HIV-infected cell
10 HIV-infected patient
11 HIV-specific T cell
12 Langerhans cell
13 Ml
14 Phase II
15 active pharmaceutical ingredient
16 antiretroviral activity
17 antiretroviral therapy
18 arm
19 arm 2
20 cm2
21 dose
22 dose finding
23 high dose
24 immunization
25 immunization schedule
26 immunogenicity
27 integration
28 low dose
29 lymph node
30 medium
31 multi-center study
32 multicenter study
33 nanomedicine
34 particle
35 patch
36 patient
37 placebo
38 plasmid
39 primary endpoint
40 replication
41 reverse transcription
42 right
43 safety
44 skin
45 tolerability
46 topical administration
47 unit
48 schema:name A Phase II Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antiretroviral Activity of DermaVir Patch (LC002) in Treatment-Naïve HIV-1-Infected Patients
49 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT00711230
50 schema:sdDatePublished 2019-03-07T15:23
51 schema:sdLicense https://scigraph.springernature.com/explorer/license/
52 schema:sdPublisher N45a788ddc38d4447b799cc05049052c6
53 schema:sponsor https://www.grid.ac/institutes/grid.13648.38
54 https://www.grid.ac/institutes/grid.459389.a
55 https://www.grid.ac/institutes/grid.491914.0
56 schema:startDate 2008-04-01T00:00:00Z
57 schema:subjectOf sg:pub.10.1111/j.0022-202x.2004.23535.x
58 https://doi.org/10.1016/j.ijpharm.2010.03.048
59 https://doi.org/10.1016/j.nano.2011.07.013
60 https://doi.org/10.1016/j.nano.2012.05.012
61 https://doi.org/10.1016/j.vaccine.2005.01.004
62 https://doi.org/10.1016/j.vaccine.2007.01.024
63 https://doi.org/10.1016/j.vaccine.2010.11.019
64 https://doi.org/10.1097/00002030-200501030-00004
65 https://doi.org/10.1371/journal.pone.0035416
66 https://doi.org/10.1586/erv.11.118
67 schema:url https://clinicaltrials.gov/show/NCT00711230
68 sgo:license sg:explorer/license/
69 sgo:sdDataset clinical_trials
70 rdf:type schema:MedicalStudy
71 N45a788ddc38d4447b799cc05049052c6 schema:name Springer Nature - SN SciGraph project
72 rdf:type schema:Organization
73 anzsrc-for:3053 schema:inDefinedTermSet anzsrc-for:
74 rdf:type schema:DefinedTerm
75 sg:pub.10.1111/j.0022-202x.2004.23535.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1003763955
76 https://doi.org/10.1111/j.0022-202x.2004.23535.x
77 rdf:type schema:CreativeWork
78 https://doi.org/10.1016/j.ijpharm.2010.03.048 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049047381
79 rdf:type schema:CreativeWork
80 https://doi.org/10.1016/j.nano.2011.07.013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042808998
81 rdf:type schema:CreativeWork
82 https://doi.org/10.1016/j.nano.2012.05.012 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004651059
83 rdf:type schema:CreativeWork
84 https://doi.org/10.1016/j.vaccine.2005.01.004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000998801
85 rdf:type schema:CreativeWork
86 https://doi.org/10.1016/j.vaccine.2007.01.024 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040396586
87 rdf:type schema:CreativeWork
88 https://doi.org/10.1016/j.vaccine.2010.11.019 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011308805
89 rdf:type schema:CreativeWork
90 https://doi.org/10.1097/00002030-200501030-00004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009052805
91 rdf:type schema:CreativeWork
92 https://doi.org/10.1371/journal.pone.0035416 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052753685
93 rdf:type schema:CreativeWork
94 https://doi.org/10.1586/erv.11.118 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029275935
95 rdf:type schema:CreativeWork
96 https://www.grid.ac/institutes/grid.13648.38 schema:Organization
97 https://www.grid.ac/institutes/grid.459389.a schema:Organization
98 https://www.grid.ac/institutes/grid.491914.0 schema:Organization
 




Preview window. Press ESC to close (or click here)


...